Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial Meeting Abstract
| Authors: | Bourlon, M. T.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; Richardet, M.; Gurney, H.; Kessler, E. R.; Tomita, Y.; Bedke, J.; Wang, F.; Wang, P. T.; Panzica, J.; Fedorov, V.; Motzer, R. J.; Choueiri, T. K. |
| Abstract Title: | Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900054 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.362 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 362 -- Source: Wos |
